04.04.2013 Views

Transcriptional Characterization of Glioma Neural Stem Cells Diva ...

Transcriptional Characterization of Glioma Neural Stem Cells Diva ...

Transcriptional Characterization of Glioma Neural Stem Cells Diva ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

3.2 Brain Cancer <strong>Stem</strong> <strong>Cells</strong> Introduction<br />

CDK1 and CDK2 was significantly higher in CD133 + cells than in CD133 - cells,<br />

indicating that the former show greater checkpoint activation in response to<br />

DNA damage. The fact that CD133 + glioma cells demonstrated to activate<br />

checkpoint responses to a greater extent than CD133 - cells, suggested that the<br />

resistance <strong>of</strong> CD133 + cells to ionizing radiation is due to preferential check-<br />

point activation. The finding that CD133 + cells were made less resistant to<br />

radiation if the checkpoint kinases CDK1 and CDK2, which control the pauses<br />

in cell-cycle progression that are scheduled for DNA repair to occur (Fig 3.3),<br />

were to be pharmacologically inhibited, provided the potential for a cure tar-<br />

geting the resilient stem cell mass. The CD133 + resistant population should be<br />

Figure 3.3: The cell cycle <strong>of</strong> eukaryotic cells can be divided into four successive<br />

phases: M for mitosis, S for DNA synthesis, and two gap phases, G1 and G2. In<br />

the G1 phase extracellular cues may induce either commitment to a further round <strong>of</strong><br />

cell division or withdrawal from the cell cycle into G0 to embark on a differentiation<br />

pathway. The G1 phase is also involved in the control <strong>of</strong> DNA integrity before the<br />

onset <strong>of</strong> DNA replication. During the G2 phase the cell checks the completion <strong>of</strong><br />

DNA replication and the genomic integrity before cell division starts. Adapted from<br />

Dehay et al 2007 [115].<br />

targeted with DNA checkpoint blockers to make these cells radiosensitive and<br />

thus, in one therapy cycle, potentially wipe out the entire tumour mass (Fig<br />

3.4) [123]. Together, the results exposed by Bao et al showed that CD133 +<br />

cancer cells contributed to glioma radioresistance and tumour re-population<br />

through preferential checkpoint response and DNA repair, and targeting <strong>of</strong><br />

checkpoint response in CD133 + cancer cells can overcome glioma radioresis-<br />

tance in vitro and in vivo, which may provide a therapeutic advantage to<br />

reduce brain tumour recurrence [40].<br />

67

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!